All obesity articles
-
OpinionGLP-1 drugs could be more than a win–win for weight loss
Semaglutide and tirzepatide are changing lives, and could change our attitudes
-
NewsWeight-loss drugmakers bet billions on boosting supplies
Eli Lilly and Novo Nordisk invest to expand in-house manufacturing of GLP-1 drugs
-
BusinessNovo Holdings to buy contract manufacturer Catalent for $16.5 billion
Parent firm will then sell on three manufacturing sites to Novo Nordisk to boost capacity for diabetes and weight loss drugs
-
OpinionCompounding problems
Regulating the line between a vital service and grey-market profiteering is a mess
-
BusinessWeight-loss drug shortages prompt copycats and counterfeits
Novo Nordisk and Eli Lilly have struggled to meet huge demand for new hormone mimic obesity treatments
-
BusinessThe diabetes drugs aiming to aid weight loss
Can peptide hormone mimics avoid the side effect pitfalls of previous weight loss treatments?
-
FeatureAre everyday chemicals contributing to global obesity?
Research in animal models suggests the simple ‘energy in, energy out’ model doesn’t tell the whole story. Anthony King talks to researchers worried about obesogens
-
FeatureThe brain chemicals that control what we enjoy
Researchers are trying to understand how orexins influence our appetites, and whether we can use them to treat addiction and obesity, explains Andy Extance
-
ResearchArray of compounds found in plastics promote fat cell formation in vitro
A third of thousands of chemicals that leach from consumer polymers linked to the development of fat cells
-
PodcastThe Truth About Fat by Anthony Warner – Book club
‘Angry chef’ Anthony Warner wants you to understand why people really get fat and how society tricks us into blaming each other
-
FeatureThe battle to lose weight
Losing weight – and not putting it back on – is about much more than willpower. Nina Notman reports on the drugs trying to penetrate the complex metabolic web of hunger and satiety.
-
ResearchBrain chemistry hints at how obesity impairs antidepressants
Histamine released in response to obesity or bacterial toxins prevents benefits from SSRIs – and that drugs that target these inflammatory signals may restore them
-
-
-
-
-
ResearchBacterium altered to suppress hunger faces long road to clinic
Engineered microbes produce anti-obesity molecule in mice, but moving to humans poses challenges
-
NewsEU tightens drug rules in wake of Mediator scandal
Withdrawal of a drug in one EU member state will trigger an alert throughout the rest
-
BusinessObesity drug approved in US
Qsymia from Vivus joins Belviq in a lucrative part of the pharma industry
-
News
FDA green lights new obesity drug
Agency approval for prescription only obesity drug is first for 13 years